Results 131 to 140 of about 3,003 (174)

Recent Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Engineering Strategies for Precise Strike Therapy against Tumor. [PDF]

Biomater Res
Lee CE, Noh KM, Kim S, Hong J, Kim K.
europepmc   +1 more source

A Novel Integrated Strategy for Discovering Absorbable Anticoagulant Bioactive Peptides: A Case Study on Leech Protein Hydrolysates. [PDF]

Molecules
Fang KX, Sun X, Chen LK, Wang K, Yang CJ, Mei SS, Huang CY, Yang YJ.   +7 more
europepmc   +1 more source

PGC1-Alpha/Sirt3 Signaling Pathway Mediates the Anti-Pulmonary Fibrosis Effect of Hirudin by Inhibiting Fibroblast Senescence. [PDF]

Biomedicines
He B, Zeng Q, Tian Y, Luo Y, Liao M, Huang W, Wu B, Luo Z, Huang X, Liu W, Tang S.   +10 more
europepmc   +1 more source

Study on the mechanism of hirudin multi target delaying renal function decline in chronic kidney disease based on the "gut-kidney axis" theory. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Long C, Zhang C, Xie Y.
europepmc   +1 more source

Hirudin versus heparin for anticoagulation in continuous renal replacement therapy

Intensive Care Medicine, 2001
To compare the efficacy and safety of hirudin and heparin for anticoagulation during continuous renal replacement therapy (CRRT) in critically ill patients.Prospective, randomized controlled pilot study.Single centre; interdisciplinary intensive care unit at a university hospital.Seventeen patients receiving CRRT.Patients were randomly allocated to two
Claudio Ronco, H H Neumayer, Stanislao Morgera   +2 more
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Platelet-Covered Nanocarriers for Targeted Delivery of Hirudin to Eliminate Thrombotic Complication in Tumor Therapy

ACS Nano, 2022
Most patients are at high risk of thrombosis during cancer treatment. However, the major discrepancy in the therapeutic mechanisms and microenvironment between tumors and thrombosis makes it challenging for a panacea to treat cancer while being able to eliminate the risk of thrombosis.
Kai Zhang, Weiyun Zhang, Mohamed F Foda   +2 more
exaly   +5 more sources

Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK) Interim results

European Heart Journal, 1995
To evaluate the efficacy and safety of hirudin, a direct thrombin inhibitor, in patients with acute myocardial infarction, a dose-finding, angiography study was carried out. After a pilot phase in 10 patients treated with a bolus of 0.1 mg.kg-1 and a continuous infusion of 0.06 mg.kg-1.h-1 (dose group I), two doses of hirudin, bolus 0.2 mg.kg-1.h-1 (DG
G P, Molhoek, G J, Laarman, D J, Lok, C M, Luz, J H, Kingma, A A, Van den Bos, P, Zijnen, A H, Bosma, D P, Hertzberger, L H, Takens   +9 more
exaly   +3 more sources

Hirudin therapy during thrombolysis for venous thrombosis in heparin-induced thrombocytopenia

Vascular Medicine, 2000
Heparin-induced thrombocytopenia (HIT) is the most common drug-related thrombocytopenia. Thromboembolic complications occur in approximately 50% of patients with HIT and result in limb amputation and death in up to 20% and 30% respectively. Because patients with a history of HIT may require future intravenous anticoagulation but have a high-risk of ...
M P, Reilly, R, Weiss, A, Askenase, C, Tuite, M, Soulen, E R, Mohler   +5 more
openaire   +2 more sources

Monitoring of hirudin therapy with the thrombelastograph®

Journal of Clinical Anesthesia, 2002
Lepirudin is a specific thrombin inhibitor that is used for anticoagulation in patients with heparin-induced thrombocytopenia who are also undergoing cardiopulmonary bypass (CPB). Monitoring of lepirudin during CPB has been carried out with activated clotting time and ecarin clotting time.
openaire   +2 more sources